Sathekge, Mike MachabaByttebier, GeertDe Spiegeleer, BartSaxberg, BoUeckermann, VeronicaBelmans, LucAlexander, MyriamFedson, David2022-04-282022-04-282021-04-01Sathekge, M.; Byttebier, G.; De Spiegeleer, B.; Saxberg, B.; Ueckermann, V.; Belmans, L.; Alexander, M.; Fedson, D. Adjunctive Use of Statins for COVID-19. Journal of Clinical Medicine 2021, 10, 1407. https://DOI.org/10.3390/jcm10071407.2077-0383 (online)10.3390/jcm10071407https://repository.up.ac.za/handle/2263/84934The interaction between obesity, cardiometabolic disorders and COVID-19 represents a syndemic that requires both social intervention and a multipharmacological approach. The risks associated with diabetes, obesity and hypertension for severe COVID-19 may be confounded by the type of medication for these cardiometabolic factors. Furthermore, endothelial dysfunction is a common feature of the key comorbidities that increase risk for severe COVID-19 such as hypertension, obesity, diabetes mellitus, coronary artery disease or heart failure. Among the drugs used to manage hypertension and diabetes mellitus are angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and statins, all of which are known to improve endothelial dysfunction.en© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.ObesitySocial interventionRisksCOVID-19 pandemicCoronavirus disease 2019 (COVID-19)Cardiometabolic disordersAngiotensin-converting enzyme (ACE)Angiotensin receptor blockers (ARBs)StatinsEndothelial dysfunctionArticle